| telomerase inhibitor | optimal length (nt) | target | IC50 a | refs |
|---|---|---|---|---|
| oligonucleotide (DNA) | >18 nt | template | 5–460 nM | 41,42 |
| phosphorothioate (PS-DNA) | 11–13 | template, hTERT | 0.2–25 μM | 23,43 |
| 2'-O-methyl RNA (2'-OMe RNA) | 11–13 | template | 8–300 nM | 42,67 |
| 2'-O-MOE RNAb | 13 | template | 3–10 nM | 45 |
| peptide nucleic acid (PNA) | 11–13. 11–15 | template hTRd | 1–100 nM, 0.010–100 μM | 23,44,47 |
| PNA-peptide conjugates | NDc | template | 0.140–8 μM | 65 |
| ribozyme | >36 | hTR, template | 0.4–10 μM | 54–57 |
| DNA-2',5'-oligoadenylate | >19 | hTR, template | NDc | 50–53 |
a IC50 values determined with the telomere repeat-amplification protocol (TRAP) at 37°C.
b 2'-OMOE RNA: 2'-O-(2-methoxyethyl) RNA.
c ND: not determined.
d Non-template region of hTR.
From: PNA and Oligonucleotide Inhibitors of Human Telomerase
NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.